Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FX-322 safety study in severe sensorineural hearing loss
NCT04629664Phase 1Completed
- Sponsor
- Frequency Therapeutics
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in sensorineural hearing loss (SNHL) comparing FX-322 with Placebo (2 arms). Primary endpoints: Number of patients with treatment-related adverse events at 3 months, Number of patients with abnormal changes from baseline in otoscopic examinations at 3 months and 2 more. Started Nov 2020; status: completed.
02
Drugs
FX-322
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on NCT04629664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629664.